Recently, the glucagon-like peptide 1 receptor agonists (GLP-1 RA) have been extensively studied as a possible treatment for T2DM, and GLP-1 RA together with dipeptidyl peptidase-4 (DPP-4) inhibitors are now in widespread clinical use in these patients [14]. Here, GLP1R is linked to type 2 diabetes mellitus.